Skip to content

MAZE MAZE Depreciation

Depreciation at other companies

Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
Zymeworks logo
ZymeworksZYME
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation

See full
Market cap$1.48B+201%
Enterprise value$1.34B
P/S7.9×

Profitability

See full
Operating margin-71.5%
Net margin-65.4%
FCF margin-65.1%

Returns & leverage

See full
Return on equity-38.7%
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×

Where this comes from

Reported directly by MAZE in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MAZE's depreciation?
MAZE (MAZE) reported depreciation of $444K in Q1 2026.
How has MAZE's depreciation changed year-over-year?
MAZE's depreciation decreased by 35.1% year-over-year, from $684K to $444K.